A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

  • Glaspole, Ian (Primary Chief Investigator (PCI))
  • Symons, Karen M. (Project Manager)

Project: Research

Project Details

Effective start/end date7/06/191/12/22


  • Respiratory diseases
  • Idiopathic pulmonary fibrosis
  • Clinical trial